The relationship between spiritual intelligence and self-management in patients with diabetes type 1
Rafiei S, Souri S, Nejatifar Z, Amerzadeh M
Diabetes Technol Ther. Pub. online 5 Sep 2023.
Leggi
Breaking news
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group
RECOVERY Collaborative Group
Lancet Diabetes Endocrinol. Pub. Online 18 Oct 2023.
Leggi
Teplizumab and β-cell function in newly diagnosed type 1 diabetes
Ramos EL, Dayan CM, Chatenoud L, et al.
NEJM. Pub. online 18 Oct 2023.
Leggi
Construction and validation of a nomogram for predicting diabetes remission at 3 months after bariatric surgery in patients with obesity combined with type 2 diabetes mellitus
Yuan K, Wu B, Zeng R, et al.
Diabetes Obes Metab. Pub. online 9 Oct 2023.
Leggi
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China
Ji L, Ahmann AJ, Ahrén B, et al.
Diabetes Obes Metab. Pub. online 12 Oct 2023.
Leggi
Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
Russell-Jones D, Babazono T, Cailleteau R, et al.
The Lancet. Pub. online 17 Oct 2023.
Leggi
CamAPS FX hybrid closed-loop with ultra-rapid lispro compared with standard lispro in adults with type 1 diabetes: a double-blind, randomized, crossover study
Nwokolo M, Lakshman R, Hartnell S, et al.
Diabetes Technol Ther. Pub. online 12 Oct 2023.
Leggi
Listening to women: experiences of using closed-loop in type 1 diabetes pregnancy
Lawton J, Kimbell B, Closs M, et al.
Diabetes Technol Ther. Pub. online 5 Oct 2023.
Leggi
Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial
Nørgaard SK, Søholm JC, Mathiesen ER, et al.
Lancet Diabetes Endocrinol. 2023:S2213-8587(23)00236-X.
Leggi
Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction
Butt JH, Docherty KF, Kosiborod MN, et al.
J Am Coll Cardiol HF. 2023, 11 (10) 1411–1423.
Leggi